Onecha VV, Suarez-García D, Bosque JJ, Lee H, Simpkins F, Gitto SB, Pryma DA, Bertolet A. Space- and Time-Defined Monte Carlo Dosimetry Explains Ovarian Cancer Cell Viability in Targeted α-Particle Therapy With Astatine 211-ParaThanatrace , Int J Radiat Oncol Biol Phys. (IF = 6.5): 2025
Smith AJB, Spataro S, Heintz J, Simpkins F, Ko EM Disparities in clinical drug trial participation in endometrial cancer: a real-world analysis. , Am J Obstet Gynecol. (Impact factor 8): 2025
Xu H, George E, Gallo D, Medvedev S, Wang X, Kryczka R, Hyer ML, Fourtounis J, Stocco R, Aguado-Fraile E, Petrone A, Yin SY, Shiwram A, Anderson M, Kim H, Liu F, Marshall CG, Simpkins F Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR. , Nature Communications (Impact factor 17): 2025
Fiona Simpkins, Alexandra Leary, Lyndsay Willmott, Bradley J. Monk, , Jean-Sébastien Frenel, David C. Starks, Meena Okera, Angeles Alvarez Secord, David M. O’Malley, Lainie Martin, Kaissa Ouali, Martin K. Oehler, Jeffrey C. Goh, Brian M. Slomovitz, Peter C. Lim, Catherine M. Shannon, Robert Neff, Doris Kim, Hailun Li, Danielle Jandial, Floor J. Backes Cyclin E1 is a Predictive Biomarker
of Azenosertib Benefit in Platinum-Resistant Ovarian Cancer (PROC): Outcomes From Part 1b of the DENALI Study (GOG-3066)
, Gynecology Oncology; plenary, SGO Annual Meeting, March 2025: 2025
Erin George, Lakeisha Mulugeta-Gordon, Emily M Ko, Sharon Wu, Joanne Xiu, Nathaniel Jones, Premal H Thaker, Thomas J Herzog, Eric J Brown, Dineo Khabele, Fiona Simpkins Impact of CCNE1 Amplification on Molecular Signatures and Patient Outcomes in High Grade Serous Ovarian and Endometrial Cancer , Gynecology Oncology; plenary, SGO Annual Meeting, March 2025: 2025
Smith AJ, Pancoe S, Lynch MP, Wachlin M, Powell K, Hinkle SN, Koelper NC, Doherty M, Bekelman JE, Simpkins F, Ko EM Rideshare services for transportation assistance in gynecologic oncology: a quality improvement study , BMC Health Serv Res: 2025
Kim D, Chung H, Liu W, Jeong K, Ozmen TY, Ozmen F, Rames MJ, Kim S, Guo X, Jameson N, de Jong PR, Yea S, Harford L, Li J, Mathews CA, Doroshow DB, Charles VJ, Kim D, Fischer K, Samatar AA, Jubb A, Bunker KD, Blackwell K, Simpkins F, Meric-Bernstam F, Mills GB, Harismendy O, Ma J, Lackner MR Cyclin E1/CDK2 activation defines a key vulnerability to WEE1 kinase inhibition in gynecological cancers , NPJ Precis Oncol (Impact Factor 8): 2025
Liu YL, Mathews CA, Simpkins F, Cadoo KA, Provencher D, McCormick CC, ElNaggar AC, Altman AD, Gilbert L, Black D, Kabil N, Taylor RN, Barnicle A, Munley JY, Aghajanian C Olaparib as treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency: Phase 2 LIGHT study final overall survival analysis , Cancer (IF = 5): 2025
Weeks JK, Pantel AR, Gitto SB, Liu F, Schubert EK, Pryma DA, Farwell MD, Mankoff DA, Mach RH, Simpkins F, Lin LL [18F]Fluorthanatrace PET in Ovarian Cancer: Comparison with [18F]FDG PET, Lesion Location, Tumor Grade, and Breast Cancer Gene Mutation Status. , J Nucl Med (IF= 9): 2025
Barnicle A, Ray-Coquard I, Rouleau E, Cadoo K, Simpkins F, Aghajanian C, Leary A, Poveda A, Lheureux S, Pujade-Lauraine E, You B, Ledermann J, Matulonis U, Gourley C, Timms KM, Lai Z, Hodgson DR, Elks CE, Dearden S, Egile C, Lao-Sirieix P, Harrington EA, Brown JS Patterns of genomic instability in > 2000 patients with ovarian cancer across six clinical trials evaluating olaparib , Genome Medicine (Impact Factor 12): 2024
